Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) COO Sells $645,500.00 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) COO Alexander O. Schuth sold 10,000 shares of the company’s stock in a transaction on Friday, June 4th. The stock was sold at an average price of $64.55, for a total value of $645,500.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Alexander O. Schuth also recently made the following trade(s):

  • On Tuesday, May 4th, Alexander O. Schuth sold 10,000 shares of Denali Therapeutics stock. The stock was sold at an average price of $55.49, for a total value of $554,900.00.
  • On Monday, April 5th, Alexander O. Schuth sold 10,000 shares of Denali Therapeutics stock. The stock was sold at an average price of $56.09, for a total value of $560,900.00.

Shares of NASDAQ:DNLI opened at $74.21 on Friday. Denali Therapeutics Inc. has a 52-week low of $22.36 and a 52-week high of $93.94. The stock has a market capitalization of $8.99 billion, a PE ratio of 322.67 and a beta of 1.91. The business has a 50-day moving average price of $58.52.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Sunday, May 2nd. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.24). Denali Therapeutics had a return on equity of 6.36% and a net margin of 17.02%. The firm had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $31.62 million. The business’s revenue for the quarter was up 119.4% compared to the same quarter last year. Equities analysts expect that Denali Therapeutics Inc. will post -1.81 earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Denali Therapeutics from a “sell” rating to a “hold” rating and set a $66.00 price objective for the company in a research note on Friday, February 19th. TheStreet upgraded Denali Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 26th. UBS Group began coverage on Denali Therapeutics in a research note on Tuesday, May 18th. They issued a “buy” rating and a $70.00 price target for the company. Finally, HC Wainwright increased their price target on Denali Therapeutics from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, March 4th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Denali Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $79.00.

Several large investors have recently made changes to their positions in the company. US Bancorp DE raised its stake in shares of Denali Therapeutics by 180.1% in the fourth quarter. US Bancorp DE now owns 395 shares of the company’s stock worth $33,000 after purchasing an additional 254 shares during the last quarter. Arizona State Retirement System grew its holdings in Denali Therapeutics by 1.2% during the first quarter. Arizona State Retirement System now owns 22,690 shares of the company’s stock worth $1,296,000 after acquiring an additional 270 shares during the period. Nisa Investment Advisors LLC grew its holdings in Denali Therapeutics by 7.7% during the first quarter. Nisa Investment Advisors LLC now owns 6,294 shares of the company’s stock worth $359,000 after acquiring an additional 450 shares during the period. ClariVest Asset Management LLC grew its holdings in Denali Therapeutics by 2.8% during the first quarter. ClariVest Asset Management LLC now owns 17,206 shares of the company’s stock worth $982,000 after acquiring an additional 473 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Denali Therapeutics during the first quarter worth about $29,000. Hedge funds and other institutional investors own 65.85% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease.

See Also: What is the Book Value of a Share?

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.